Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Vyxeos for Relapsed or Refractory Acute Leukemia in Young Patients
NCT03826992Phase 1Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Dec 2018
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute leukemia, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Dose Limiting Toxicities at 28 days and Treatment related toxicities at 60 days. Started Dec 2018; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT03826992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826992.